Pipeline Accelerator outcomes

Search and sort the table below for details on projects supported by TIA’s Pipeline Accelerator scheme.

Pipeline Accelerator Program	Lead applicant	Affiliation	Project title	Capability provider
2022-23 (Round 2)	Dr Balaji Somasundaram	Denteric Pty Ltd	Enabling translation of a therapeutic vaccine candidate against Porphyromonas gingivalis	National Biologics Facility Queensland Node
2022-23 (Round 2)	Ms Reema Bajaj	Burnet Institute	Engineering IgG-like ACE2 antivirals against future pathogenic coronavirus events	National Biologics Facility Queensland Node
2022-23 (Round 2)	Professor Fabienne Mackay	QIMR Berghofer Medical Research Institute	Large-scale production of a TACI-targeting antibody to test its therapeutic efficacy in a preclinical model of chronic lymphocytic leukaemia.	Protein Expression Facility
2022-23 (Round 2)	Dr Evan Wong	Lions Eye Institute, Sir Charles Gairdner Hospital and Royal Perth Hospital	Validation of GMP-compliant manufacture of corneal endothelial cells for intraocular injection as an alternative to corneal transplantation	Cell & Tissue Therapies WA
2022-23 (Round 2)	Associate Professor Joshua Ooi	Monash University	Manufacture of autologous T regulatory cells modified ex vivo to express T cell receptors for autoimmune disease	Centre of Excellence in Cellular Immunotherapy
2022-23 (Round 2)	Professor David Ian Roper FRSC	University of Warwick,UK	Drug discovery for bacterial glycosyltransferases to combat AMR using the Monash Fragment Platform (MFP) screening facility	Monash Fragment Platform
2022-23 (Round 2)	Associate Professor Ann Kwan	University of Sydney	Targeting FtsY for a new class of antibiotics	Monash Fragment Platform
2022-23 (Round 2)	Dr Chengxue Helena Qin	Monash University	Novel disease-modifying approach to treat pulmonary hypertension	Australian Translational Medicinal Chemistry Facility
2022-23 (Round 2)	Dr Steven Suchting	Emenda Therapeutics Australia Pty Ltd	Development of SRPK1 kinase inhibitors for osteoarthritis pain	Centre for Drug Candidate Optimisation
2022-23 (Round 2)	Dr. William Thomas Jorgensen	Psylo Pty Ltd and the University of New South Wales	Understanding the key electronic and structural features for optimal brain penetration of a subset of our novel serotonergic agonists for CNS therapeutic applications	Centre for Drug Candidate Optimisation
Technical Feasibility Assessment	A/Prof Anthony Kicic	Telethon Kids Institute	Making bacteriophage therapy a reality: Implementation of a novel treatment pipeline to treat antimicrobial-resistant infections.	Cell & Tissue Therapies WA
Technical Feasibility Assessment	A/Prof Joshua Ooi	Monash University	Manufacture of autologous T regulatory cells modified ex vivo to express T cell receptors for autoimmune disease	Centre of Excellence in Cellular Immunotherapy
Technical Feasibility Assessment	Prof Enzo Porrello	Murdoch Childrens Research Institute	Evaluating technical feasibility of cGMP production of bioengineered heart tissue to treat heart failure in congenital heart disease	Centre of Excellence in Cellular Immunotherapy
Technical Feasibility Assessment	Dr Rhonda Taylor	The University of Western Australia (UWA)	Allele-selective CRISPR deletion as a therapy for ACTA1 congenital myopathy	Cell & Tissue Therapies WA
Technical Feasibility Assessment	Dr Evan Wong	Royal Perth Hospital	Validation of GMP-compliant manufacture of corneal endothelial cells for injection	Cell & Tissue Therapies WA
2022-23 (Round 1)	Prof Philip Board	Omega-One Therapeutics Pty. Ltd.	Developing Glutathione transferase Omega 1 inhibitors as anti-inflammatory therapeutics	Australian Translational Medicinal Chemistry Facility
2022-23 (Round 1)	Prof Enzo Porrello	Murdoch Children’s Research Institute	Developing next generation cardio-regenerative therapeutics to treat systolic heart failure	Australian Translational Medicinal Chemistry Facility
2022-23 (Round 1)	Dr Richard Foitzik	Oncology One Pty Ltd	ADME investigation into methyltransferase inhibitor candidates	Centre for Drug Candidate Optimisation
2022-23 (Round 1)	Ms Filippa Shub	Inosi Therapeutics	IRAP inhibitor lead optimisation	Centre for Drug Candidate Optimisation
2022-23 (Round 1)	Prof Mark von Itzstein	Institute for Glycomics, Griffith University	Development of drug candidates against drug resistant bacteria	Centre for Drug Candidate Optimisation
2022-23 (Round 1)	Prof Brian Gabrielli	Mater Research Institute	Screen for compounds synthetically lethal with defective RB and p53	Discovery Biology Griffith
2022-23 (Round 1)	Mr Robert Batchelor	Nutromics Pty Ltd	Surface plasmon resonance-based screening of DNA aptamers targeted to small molecule drugs	Monash Fragment Platform
2022-23 (Round 1)	Dr Jacek Kwiatkowski	Queensland Emory Drug Discovery Initiative	Identification of Inhibitors of a Key Necroptotic Protein Through Fragment Screening	Monash Fragment Platform
2022-23 (Round 1)	Prof Alastair Stewart	University of Melbourne	Discovery of selective inhibitors for fibrosis	Monash Fragment Platform
2022-23 (Round 1)	Mr Paul Fahey	Vaxxas Pty. Ltd.	Enhanced skin delivery of vaccines by manipulating surface interactions on High Density Micro Array Patches (HD-MAP’s).	National Biologics Facility Victoria Node
2022-23 (Round 1)	A/Prof Daniel Thomas	University of Adelaide	Anti-mutant CALR Antibody Preparation for Clinical Manufacture for Patients with Myelofibrosis	National Biologics Facility Queensland Node
2022-23 (Round 1)	Dr Graham Heery	Starpharma Pty Ltd	Production of a HER2 binding nanobody for the assembly of targeted novel dendrimer therapeutics for breast and gastric cancer	Protein Expression Facility
2022-23 (Round 1)	Prof James St John	Griffith University	Spinal Injury Project: pilot-scale GMP production and validation of clinically compliant nerve bridges	Q-Gen Cell Therapeutics
2022-23 (Round 1)	Dr Steve Dingwall	Australian Institute for Bioengineering and Nanotechnology	Generation of Induced Pluripotent Stem Cell Master and Working Cell Banks for a Phase 1 Clinical Trial for the Treatment of Heart Failure	Q-Gen Cell Therapeutics
2022-23 (Round 1)	Prof Andrew Elefanty	Murdoch Children’s Research Institute	Building a better leukaemia – Modeling paediatric acute myeloid leukaemia in pluripotent stem cells	Stafford Fox Disease Modelling Facility
2022-23 (Round 1)	A/Prof Silvia Velasco	Murdoch Children’s Research Institute	Development of a platform for the automated generation and high-throughput drug screening of brain organoids	Stafford Fox Disease Modelling Facility
2022-23 (Round 1)	Prof Robyn Jamieson	Children’s Medical Research Institute	Long-term AAV-mediated genetic rescue of photoreceptors in retinitis pigmentosa	Sydney Cell and Gene Therapies
2022-23 (Round 1)	A/Prof James Chong	Westmead Institute for Medical Research	Process development for the preparation and delivery of induced pluripotent stem cell derived cardiomyocytes for end stage heart failure.	Sydney Cell and Gene Therapy
2022-23 (Round 1)	A/Prof Elaine Sanij	St Vincent’s Institute of Medical Research	Development of new cancer therapeutics targeting the nucleoli	Victorian Centre for Functional Genomics
2021-22 (Round 2)	Prof Christopher Langmead	Monash Institute of Pharmaceutical Sciences	Development of novel agonists for schizophrenia	Australian Translational Medicinal Chemistry Facility
2021-22 (Round 2)	Prof Roland Stocker	Heart Research Institute	Synthesis of a novel PET probe to detect plaque activity for the identification of high-risk atherosclerosis	Australian Translational Medicinal Chemistry Facility
2021-22 (Round 2)	Dr Thomas Theodor Tapmeier	Monash University	NPSR1 Antagonist in Endometriosis	Australian Translational Medicinal Chemistry Facility
2021-22 (Round 2)	Prof Ian Smyth	Monash University	Pharmacokinetic assessment and optimisation of a new therapy for PKD	Australian Translational Medicinal Chemistry Facility and Centre for Drug Candidate Optimisation
2021-22 (Round 2)	A/Prof Ethan D. Goddard-Borger	Walter and Eliza Hall Institute of Medical Research	Development of anthelmintics with a novel mode of action	Centre for Drug Candidate Optimisation
2021-22 (Round 2)	Dr William Thomas Jorgensen	Psylo Pty Ltd	Pre-clinical development of novel serotonergic agents for therapeutic applications in mental illness	Centre for Drug Candidate Optimisation
2021-22 (Round 2)	Dr Sohinee Sarkar	Murdoch Children’s Research Institute	A new treatment for the cystic fibrosis superbug, Mycobacteroides abscessus	Compounds Australia
2021-22 (Round 2)	Dr Nicole Van Bergen	Murdoch Children’s Research Institute	Utilising high-throughput drug screening for mitochondrial metabolite repair disorders	Compounds Australia
2021-22 (Round 2)	Dr Katherine Locock	CSIRO	Accelerated antibiotic discovery through high-throughput	Compounds Australia and Community for Open Antimicrobial Drug Discovery
2021-22 (Round 2)	A/Prof Rebecca Lim	Prescient Therapeutics	Preclinical toxicity studies for OmniCAR-enabled targeting ligands	National Biologics Facility Queensland Node
2021-22 (Round 2)	Prof Kristen Radford	Mater Research Institute	Development of human CLEC9A antibodies as cancer vaccines	National Biologics Facility Queensland Node
2021-22 (Round 2)	Dr Sarah Jones	Monash University	A novel Glucocorticoid (GC) mimic for the treatment of inflammatory and autoimmune diseases	National Biologics Facility Victoria Node
2021-22 (Round 2)	A/Prof Rebecca Lim	Hudson Institute of Medical Research	Phase II Amnion Cell Therapy in Ischemic Stroke	Q-Gen Cell Therapeutics
2021-22 (Round 2)	Prof Timothy Stinear	University of Melbourne	A high-throughput screening campaign to find inhibitors of intracellular multi-drug resistant Staphylococcus aureus	Victorian Centre for Functional Genomics
2021-22 (Round 2)	A/Prof Kara Britt	Peter MacCallum Cancer Centre	Identify drugs that selectively inhibit oestrogen receptor positive luminal progenitor activity	Victorian Centre for Functional Genomics
2021-22 (Round 1)	Prof Ian Smyth	Monash University	Inhibiting cyst formation in polycystic kidney disease with targeted protein degraders (TPDs)	Australian Translational Medicinal Chemistry Facility
2021-22 (Round 1)	A/Prof Nick Clemons	Peter MacCallum Cancer Centre	Synthesis of novel small molecule inhibitors of SLC7A11/XCT for mutant-p53 cancers	Australian Translational Medicinal Chemistry Facility
2021-22 (Round 1)	Dr Robert Feldman	COVID-19 Vaccine Corporation	Development of an mRNA cytotoxic T-cell COVID-19 vaccine	BASE Facility
2021-22 (Round 1)	Dr Willem Joost Lesterhuis	Telethon Kids Institute	Development of small molecule drugs in immuno-oncology	Centre for Drug Candidate Optimisation
2021-22 (Round 1)	A/Prof Jonathan S. Oakhill	St Vincent’s Institute of Medical Research	Development of CaMKK2 inhibitors as new cancer therapies	Centre for Drug Candidate Optimisation
2021-22 (Round 1)	Dr Samantha South	Argenica Therapeutics Ltd	Neuroprotective efficacy of poly-argine-18 (R18) in a relapsing-remitting experimental autoimmune encephalomyelitis (RR-EAE) mouse model of multiple sclerosis (MS)	Centre for Integrated Preclinical Drug Development
2021-22 (Round 1)	Dr Ben Rollo	Monash University	Human high-throughput in-vitro phenotypic screening for new epilepsy drugs	Compounds Australia
2021-22 (Round 1)	Prof Sudha Rao	QIMR Berghofer	Identification of a small molecule inhibitor for therapeutic targeting of a novel nuclear methyltransferase in immunotherapy-resistant metastatic cancers	GRIDD Mass Spectrometry Screening
2021-22 (Round 1)	A/Prof Jenny Gunnersen	University of Melbourne	Screening for therapeutic antibodies to treat chronic pain	National Biologics Facility Queensland Node
2021-22 (Round 1)	Prof John Hooper	Mater Research Institute	Process development to optimise and characterise the conjugation process of DFO and monoclonal antibody 10D7	National Biologics Facility Victoria Node
2021-22 (Round 1)	Dr Nicholas Hunt	University of Sydney	Synthesis and characterisation of Ag2S quantum dots and conjugation to insulin at CSIRO	National Biologics Facility Victoria Node
2021-22 (Round 1)	Dr Chisha Teza Sikazwe	PathWest Laboratory Medicine WA	Development of recombinant MVEV and JEV NS1 antigen for the detection of JEV and MVEV antibody in serum	Protein Expression Facility
2021-22 (Round 1)	Prof Rajiv Khanna	QIMR Berghofer	The establishment of a repository of in vitro-expanded cytomegalovirus-specific T cells for the treatment of glioblastoma multiforme	Q-Gen Cell Therapeutics
2021-22 (Round 1)	Prof John EJ Rasko	Centenary Institute	Novel gene therapy platforms for hemophilia B	Vector and Genome Engineering Facility
2021-22 (Round 1)	Dr Gonzalo Perez-Siles	ANZAC Research Institute	Development of a high throughput screening platform of patient-derived iPSC motor neuron for enhancers of energy metabolism as a therapeutic intervention in axonal degeneration	Victor Chang Cardiac Research Institute
2021-22 (Round 1)	Dr Marie Besnier	University of Sydney	Treating the mitochondria to improve endothelial function of patients with coronary artery disease	Victor Chang Cardiac Research Institute
2021-22 (Round 1)	Dr Mitchell Lawrence	Monash University	New generation combination therapies for advanced prostate cancer	Victorian Centre for Functional Genomics
2020-21 (Round 2)	Dr Chengxue Helena Qin	Monash University	Next generation formyl peptide receptor 2 agonists to treat pulmonary hypertension	Australian Translational Medicinal Chemistry Facility
2020-21 (Round 2)	Dr Mitali Sarkar-Tyson	University of Western Australia	Advanced development of therapeutics against bacterial pathogens of biowarfare concern	Australian Translational Medicinal Chemistry Facility
2020-21 (Round 2)	A/Prof Daniel Thomas	University of Adelaide	Iterative design of selective Type II JAK2 Inhibitor for superior management of myelofibrosis	Australian Translational Medicinal Chemistry Facility
2020-21 (Round 2)	Dr Nadia Warner	Peter Doherty Institute for Infection and Immunity	Synthesis and development of targeted degraders of the hepatitis B virus (HBV) core proteins for HBV therapy	Australian Translational Medicinal Chemistry Facility
2020-21 (Round 2)	Dr Mark Devlin	Aculeus Therapeutics Pty Ltd	Systemically delivered small molecule STING agonists as next generation cancer immunotherapies	Centre for Drug Candidate Optimisation
2020-21 (Round 2)	Dr Paul Stupple	CTx/Monash University	In vivo and in vitro pharmacokinetic studies of novel therapeutics against blood cancers	Centre for Drug Candidate Optimisation
2020-21 (Round 2)	Dr Chris Langmead	Monash University	Development of biased agonists for schizophrenia	Centre for Drug Candidate Optimisation and Australian Translational Medicinal Chemistry Facility
2020-21 (Round 2)	Dr Pegah Varamini	University of Sydney	Development of novel therapeutics for targeted therapy of triple negative breast cancer	Centre for Integrated Preclinical Drug Development
2020-21 (Round 2)	Dr Julian Barden	Biosceptre Aust Pty Ltd	Development of novel cellular cancer therapeutics	National Biologics Facility NSW Node
2020-21 (Round 2)	A/Prof Ashley Buckle	Monash University	Development of novel anti-inflammatory biologics	National Biologics Facility Queensland Node
2020-21 (Round 2)	Prof Elizabeth Coulson	University of Queensland	Therapeutic antibody discovery to block neurotrophin receptor cleavage	National Biologics Facility Queensland Node
2020-21 (Round 2 – Screening)	A/Prof Ian Street	Children’s Cancer Institute	Development of an assay system to identify CNS-penetrant derivatives of pre-existing drugs for brain cancer	ACRF Drug Discovery Centre
2020-21 (Round 2 – Screening)	Prof Klaus-Martin Schulte	Australian National University	Identifying therapeutics for the treatment of advanced BRCA2 breast cancer”	ANU Centre for Therapeutic Discovery
2020-21 (Round 2 – Screening)	Prof Mark Dawson	Peter MacCallum Cancer Centre	Identification of novel immune-checkpoint therapies to inhibit interaction between PD-L1 and CMTM6, a new regulator of anti-tumour immunity	Discovery Biology
2020-21 (Round 2 – Screening)	Dr Jess Tiffen	Centenary Institute	Identifying Epigenetic Drivers of Drug Resistant Melanoma	Discovery Biology
2020-21 (Round 2 – Screening)	A/Prof Ethan D. Goddard-Borger	WEHI	Developing fucosyltransferase inhibitors as treatments for rare leukaemia	Monash Fragment Platform
2020-21 (Round 2 – Screening)	Dr Ueli Nachbur	WEHI	Identification of small molecule binders to Deubiquitinases	Monash Fragment Platform
2020-21 (Round 2 – Screening)	Prof Frederic Hollande	University of Melbourne	Developing a combined small molecule and immune cell killing assay to identify new therapeutics in pancreatic cancer”	Victorian Centre for Functional Genomics
2020-21 (Round 1)	Dr Mark Del Borgo	Monash University	Synthesis of novel peptide mimics for use as anti-fibrotic agents	Australian Translational Medicinal Chemistry Facility
2020-21 (Round 1)	Prof. Ian Smyth	Monash University	Inhibiting cystogenesis in Polycystic Kidney Disease with AURKA PROTACs	Australian Translational Medicinal Chemistry Facility
2020-21 (Round 1)	Dr. Christopher Burns	MycRx Pty Ltd	Novel, small-molecule therapeutics for the treatment of cancers addicted to the oncoprotein Myc	Centre for Drug Candidate Optimisation
2020-21 (Round 1)	Prof. Alastair Stewart	Tianli Biotech Pty Ltd	Development of casein kinase 1 delta inhibitors for inflammation, fibrosis and fibrotic cancers	Centre for Drug Candidate Optimisation
2020-21 (Round 1)	Dr. Fernando S. F. Guimaraes	University of Queensland	Development of new anti-breast cancer antibodies for natural killer (NK) cell-based immunotherapy	National Biologics Facility Queensland Node
2020-21 (Round 1)	Prof. John Hooper	Mater Research Institute	Production and Stability Study of 5 variants of 10D7 antibody	National Biologics Facility Queensland Node
2020-21 (Round 1)	Prof. Alex Loukas	James Cook University	Innovative IBD biologics inspired by host-parasite coevolution	National Biologics Facility Queensland Node
2020-21 (Round 1)	Prof. Peter Timms	University of Sunshine Coast	Development of a chlamydial vaccine for koalas: Production of chlamydial proteins at high quality suitable for vaccine trials	National Biologics Facility Victoria Node
2020-21 (Round 1)	Dr. Brad Walsh	Glytherix Ltd	Optimisation and Characterisation of Miltuximab-DFO Bioconjugation	National Biologics Facility Victoria Node
2020-21 (Round 1)	Prof. Andrew Prowse	University of Queensland	Pilot scale GMP production of cardiomyocytes derived from human pluripotent stem cells	Q-Gen Cell Therapeutics
2020-21 (Round 1)	Dr Stuart Fraser	University of Sydney	Nanions: a rapid, non-toxic nanoparticle vaccine platform	TetraQ
2020-21 (Round 1)	Prof. Suddha Rao	QIMR Berghofer Medical Research Institute	Safety and pharmacokinetics study of a novel anti-PD-L1 therapeutic to improve immunotherapy in triple-negative breast cancer	TetraQ
2020-21 (Round 1)	Prof. Mark von Itzstein	Griffith University	Preclinical development of a drug lead candidate against human parainfluenza virus – Exploratory pharmacokinetic, toxicity, and metabolic studies	TetraQ and Centre for Drug Candidate Optimisation
2020-21 (Round 1 – Screening)	Prof. Ian Street	Children’s Cancer Institute	Development of a high-throughput screening assay for a novel activated kinase ALPK1	ACRF Drug Discovery Centre
2020-21 (Round 1 – Screening)	A/Prof Marco Casarotto	Australian National University	Developing therapeutics that treat/prevent ischemia reperfusion injury (IRI)	ANU Centre for Therapeutic Discovery
2020-21 (Round 1 – Screening)	Assoc. Prof. Leonie Quinn	Australian National University	High-Throughput 3D Cell and Organism Screening for new brain cancer (glioma) treatments	ANU Centre for Therapeutic Discovery
2020-21 (Round 1 – Screening)	Prof. Sally-Ann Poulsen	Griffith University	Restoring the efficacy of chemotherapy in drug resistant cancers	Discovery Biology
2020-21 (Round 1 – Screening)	Prof. Murray Whitelaw	University of Adelaide	Discovery and development of new antimicrobials to combat antibiotic resistance	GRIDD Mass Spectrometry Screening Platform
2020-21 (Round 1 – Screening)	Dr Shom Goel	Peter MacCallum Cancer Centre	Improving outcomes for breast cancer patients receiving CDK4/6 inhibitors	Victorian Centre for Functional Genomics
2020-21 (Round 1 – Screening)	Dr. Eleanor Saunders	University of Melbourne	Targeting human leishmaniasis	Victorian Centre for Functional Genomics
COVID-19 (2020)	Dr Arun Konagurthu	Monash University	Modelling, synthesis and testing of potential agents against COVID-19 main protease	Australian Translational Medicinal Chemistry Facility
COVID-19 (2020)	Dr Charles Bailey	Centenary Institute	Monitoring the therapeutic efficacy of BD-218, a human neutralising monoclonal antibody against SARS-CoV-2, in COVID-19 patients using Nanostring gene expression analysis	Cell & Molecular Therapies, Royal Prince Alfred Hospital
COVID-19 (2020)	Prof Bevyn Jarrott	Vailima Peninsula Pty Ltd	Pre-clinical development of a novel, patented small molecule to treat COVID-19 respiratory injury	Centre for Drug Candidate Optimisation
COVID-19 (2020)	Dr Richard Angell	University College London	Using fragment-based drug discovery to identify small molecule inhibitors of SARS-CoV-2 (COVID-19) RNA-dependent RNA polymerase (RdRp) and future starting points for other Coronaviruses	Monash Fragment Platform
COVID-19 (2020)	Prof John Hayball	Sementis Ltd/UniSA	Large-scale manufacture of the Sementis Copenhagen Vector (SCV) COVID-19 vaccine	National Biologics Facility Victoria Node
COVID-19 (2020)	Prof Terrance Johns	Telethon Kids Institute	Discovery of antibodies to the furin cleavage site of SARS-CoV-2 Spike Glycoprotein	National Biologics Facility Queensland Node
COVID-19 (2020)	A/Prof Severine Navarro	QIMR Berghofer Medical Research Institute	Prevention of COVID-19-induced hyperinflammatory syndrome with the immunomodulatory protein AIP-2”	National Biologics Facility Queensland Node
COVID-19 (2020)	Dr Keith Dredge	Zucero Therapeutics Ltd	Analytical and bioanalytical development of pixatimod (ZU545/PG545)- a clinical candidate for cancer with anti-viral and anti-inflammatory properties – to support clinical testing for Covid-19”	TetraQ
COVID-19 (2020)	Dr Cameron Stewart	Australian Centre for Disease Prevention (ACDP), CSIRO	Defining the role of host microRNAs in COVID-19”	Victorian Centre for Functional Genomics
2019-20 (Screening)	Prof Brian Gabrielli	TRI	Screen for new agents to selectively kill a novel defect in melanomas	ACRF Drug Discovery Centre
2019-20 (Screening)	Dr Joseph Brock	ANU	Development of an engineered thermal shift assay for the high-throughput discovery of integral membrane protein lead compounds	ANU Centre for Therapeutic Discovery
2019-20 (Screening)	Dr Amee George	ANU	Identifying therapeutics for the treatment of Myelodysplastic Syndrome	ANU Centre for Therapeutic Discovery
2019-20 (Screening)	Prof Si Ming Man	ANU	Novel antitoxin compound discovery for the treatment of antibiotic resistant bacteria	ANU Centre for Therapeutic Discovery
2019-20 (Screening)	Dr Nicholas Eyre	University of Adelaide	Development of inhibitors of dengue virus (DENV) NS1 protein dimerization as novel antiviral therapeutics	Cell Screen SA
2019-20 (Screening)	Dr Benjamin Blasco	GARDP	The discovery and development of novel antibiotics against MDR and XDR Gram-negative pathogens	CO-ADD
2019-20 (Screening)	Ms Natasa Broit	QIMR Berghofer	Identification of novel therapies for the treatment of acral lentiginous melanoma	Griffith Discovery Biology
2019-20 (Screening)	Dr Brian Dymock	UniQuest	Identification of Inhibitors of a key oncogenic protein by Fragment Screening	Monash Fragment Platform
2019-20 (Screening)	Dr Dane Cheasley	Peter MacCallum Cancer Institute	High throughput investigation of synergistic drug combinations for patients with low-grade serous ovarian carcinoma	Victorian Centre for Functional Genomics
2019-20 (Screening)	Dr Nicholas Clemons	Peter MacCallum Cancer Institute	A specific inhibitor of SLC7A11 (XCT) for single agent or combination treatment of cancers with mutant p53	Victorian Centre for Functional Genomics
2019-20 (Screening)	Dr Kathleen Pishas	Peter MacCallum Cancer Institute	Defining the role of clonal interaction in high grade serous ovarian cancer drug resistance	Victorian Centre for Functional Genomics
2019-20 (Screening)	Dr Michael Sharp	St. Vincent’s Institute of Medical Research	Inhibiting the Fanconi Anaemia pathway to target BRCA1/2 negative breast and ovarian cancers	Victorian Centre for Functional Genomics
2019-20 (Core facilities)	Dr David Elliott	Murdoch Children’s Research Institute	Identifying compounds that protect against anthracycline induced heart damage	Australian Translational Medicinal Chemistry Facility
2019-20 (Core facilities)	Prof Tom Gonda	University of South Australia	Development of a small molecule inhibitor of the MYB oncogene as a therapeutic for Acute Myeloid Leukaemia	Australian Translational Medicinal Chemistry Facility
2019-20 (Core facilities)	Dr Steven Petratos	Monash University	Development of Small Molecules to Promote Remyelination in Multiple Sclerosis	Australian Translational Medicinal Chemistry Facility
2019-20 (Core facilities)	Mr Gregory Santamaria	Cyclotek (Aus) Pty Ltd	Development of advanced and novel radioligands for Positron Emission Tomography (PET) imaging	Australian Translational Medicinal Chemistry Facility
2019-20 (Core facilities)	Prof Katherine Andrews	Griffith Institute for Drug Discovery (GRIDD)	Pre-clinical optimisation studies on a new antimalarial drug lead	Centre for Drug Candidate Optimisation
2019-20 (Core facilities)	Dr Ebony Fietz	Gertrude Biomedical Pty Ltd	Preclinical ADME and PK drug properties of novel inhibitors of SOX18 transcription factor	Centre for Drug Candidate Optimisation
2019-20 (Core facilities)	Dr Wim Meutermans	Vast Bioscience Pty Ltd	ADME and PK evaluation of VAST preclinical candidates for postsurgical pain	Centre for Drug Candidate Optimisation
2019-20 (Core facilities)	Prof Bernard Flynn	Monash University	Targeting Sphingosine Kinase 1 for the Treatment of Pulmonary Hypertension	Centre for Drug Candidate Optimisation and TetraQ
2019-20 (Core facilities)	Dr Nicholas Veldhuis	Monash University	Assessing efficacy of analgesic nanoparticles in chemotherapy-induced neuropathic pain	Centre for Integrated Preclinical Drug Development
2019-20 (Core facilities)	A/Prof Brendon Coventry	Cancuravax Pty Ltd	Melanoma Cancer Vaccine Immunotherapy Production & Scaling for Commercialisation	National Biologics Facility NSW Node
2019-20 (Core facilities)	Dr Brad Walsh	GlyTherix Ltd	Production and Lead Selection of Humanised Anti-Glypican-1 Antibodies	National Biologics Facility NSW Node
2019-20 (Core facilities)	Kevin Isch	NeuClone Pty Ltd	Development and validation of an ECL immunoassay method for quantitation of ustekinumab concentration in human serum (TetraQ Study Code NEU-005); Quantification of ustekinumab concentration in human serum samples (TetraQ Study Code NEU-006); Development and validation of an ECL immunoassay method for detection of ustekinumab anti-drug antibody (ADA) response in human serum (TetraQ Study Code NEU-007); Analysis of serum samples for ustekinumab ADA response (TetraQ Study Code NEU-008)	TetraQ
2017-18	Dr Christopher J Burns	Metabloq Pty Ltd	High Throughput Screening of Compound Libraries against a Novel Cancer Metabolism Drug Target	ACRF Drug Discovery Centre for Childhood Cancer
2017-18	Dr Glen Carter	Peter Doherty Institute/ BioCurate	Development of Novel Gut-Targeted Antibiotics for the Treatment of Multidrug-Resistant Pathogens	Australian Translational Medicinal Chemistry Facility
2017-18	Prof. Spencer Williams	University of Melbourne	Pharmacokinetics and distribution of novel non-steroidal asthma drugs	Centre for Drug Candidate Optimisation
2017-18	Dr Guy Krippner	Baker IDI	Novel Receptor Agonists for difficult to treat chronic illness	Centre for Drug Candidate Optimisation and Australian Translational Medicinal Chemistry Facility
2017-18	Dr Susie Nilson	CSIRO	Toxicology and pharmacokinetic profiling of a stem cell mobilisation agent	Centre for Drug Candidate Optimisation and TetraQ
2017-18	Dr Natalie Borg	Monash University	A broad-spectrum antiviral target and anticancer target	Compounds Australia
2017-18	Prof. Charles Mackay	Monash University	Developing an agonistic antibody	Monash Antibody Technologies Facility
2017-18	Prof. Rajiv Khanna	QIMR Berghofer	The establishment of a repository of in vitro-expanded T cells for the treatment of viral complications in transplant recipients	Q-Gen Cell Therapies

Generated by wpDataTables

Search and sort the table below for details on projects supported by TIA’s Pipeline Accelerator scheme.

Contact us